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Profiling post-mortem human brains <p>Comparison of the gene expression profiles of pre- and post-mortem human brains suggests that post-mortem human brain samples  are suitable for investigating general gene-expression patterns.</p>
Abstract
Background: Numerous studies have employed microarray techniques to study changes in gene
expression in connection with human disease, aging and evolution. The vast majority of human
samples available for research are obtained from deceased individuals. This raises questions about
how well gene expression patterns in such samples reflect those of living individuals.
Results: Here, we compare gene expression patterns in two human brain regions in postmortem
samples and in material collected during surgical intervention. We find that death induces significant
expression changes in more than 10% of all expressed genes. These changes are non-randomly
distributed with respect to their function. Moreover, we observe similar expression changes due
to death in two distinct brain regions. Consequently, the pattern of gene expression differences
between the two brain regions is largely unaffected by death, although the magnitude of differences
is reduced by 50% in postmortem samples. Furthermore, death-induced changes do not contribute
significantly to gene expression variation among postmortem human brain samples.
Conclusion: We conclude that postmortem human brain samples are suitable for investigating
gene expression patterns in humans, but that caution is warranted in interpreting results for
individual genes.
Background
Microarray studies examining gene expression profiles of
thousands of genes have become an important tool in uncov-
ering molecular mechanisms of human diseases, aging and
evolution [1-3]. Many such studies are conducted on post-
mortem human tissues, since neither cell culture nor animal
models can fully recapitulate relevant human conditions
[4,5]. This is particularly the case for studies that examine the
human brain. Several factors may alter gene expression pro-
files in postmortem human brain samples. Such factors
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include the delay between death and the time of tissue freez-
ing, the method of freezing, and the duration of storage of the
frozen brain material. Prior studies have indicated that these
factors have relatively small effects on gene expression [6-8].
In contrast, the duration and nature of the agonal state pre-
c e d i n g  d e a t h  a p p e a r  t o  h a v e  a  s u b s t a n t i a l  e f f e c t  o n  g e n e
expression by affecting the integrity of messenger RNAs [7-
9]. Thus, postmortem brain samples obtained from individu-
als who died after a protracted agonal phase are not suitable
for gene expression studies. Without any prolonged agonal
conditions, however, death itself may alter gene expression
patterns in postmortem human brains. Study of expression
levels of 14 genes in human brain autopsy and biopsy samples
found significant change in one of the genes, indicating that a
substantial proportion of all expressed genes could be
affected by death [10].
We surveyed gene expression in 10 postmortem human brain
samples (autopsy samples) and 12 samples obtained from
brain surgery (resection samples) derived from frontal cortex
and hippocampus using Affymetrix® HG-U133plus2 microar-
rays containing probes for all annotated human genes. All
autopsy samples were obtained from individuals that died
rapidly with no prolonged agonal state, thus minimizing the
influence of agonal factors on gene expression patterns in our
study.
Results
Expression differences between autopsy and resection 
samples
Gene expression profiles were determined in six resection
samples from hippocampus and frontal cortex, and in four
and six autopsy samples from hippocampus and frontal cor-
tex, respectively, using Affymetrix® HG U133plus2 arrays
(see Materials and methods). Of the 54,613 probe sets on the
microarray, 42,427 (77.69%) gave a detectable hybridization
signal in at least one individual (see Materials and methods).
Among these probe sets, we found 5,703 with a significant dif-
ference in expression (13.4%) using analysis of variance
(ANOVA) with a nominal significance cutoff of 0.01 (false dis-
covery rate (FDR) = 4.12%, permutation test) and 8,643 using
significance analysis of microarrays (SAM) at the 5% FDR
cutoff. Out of the 5,703 probe sets identified in ANOVA, 5,515
(96.7%) overlapped with the probe sets identified by SAM.
Further, of these 5,703 probe sets, 4,508 differed significantly
(p < 0.01) between autopsy and resection samples in both
brain regions while 981 probe sets showed a significant differ-
ence between autopsy and resection samples as well as
between brain regions (Figure 1). For none of these 5,489
probe sets did the differences between autopsy and resection
samples depend significantly on the brain region. Finally, for
214 probe sets (0.5% of all detected ones), expression differ-
ences between autopsy and resection samples differed signif-
icantly (p < 0.01) depending on the brain region examined.
This indicates that death-induced expression changes are
highly consistent in both brain regions and influence only a
small fraction of the total observed expression differences
(214 out of 5,703).
Since all but one surgery patient were diagnosed with epilepsy
(Table 1), we first tested whether differences between autopsy
and resection samples are significantly affected by the epilep-
tic condition. Among the 42,427 expressed probe sets, we
found none with a significant effect of epilepsy either in hip-
pocampus or in frontal cortex using both linear regression
and SAM (FDR = 5.0%). Further, we tested whether known
changes in expression caused by epilepsy are over-repre-
sented among differences seen between autopsy and resec-
tion samples. Using a published set of genes where expression
change was observed in at least two epilepsy studies (N = 54)
[11], we found no such over-representation (Fisher's exact
test, p = 0.45). Finally, we tested whether expression differ-
ences we found between autopsy and resection are also seen
when only the samples unaffected by epilepsy are considered.
To this end, we identified probe sets showing expression dif-
ferences between autopsy and resection samples, excluding
from the analysis samples from patients not affected by epi-
lepsy (ANOVA, p < 0.01). We found a strong and significant
correlation when these expression differences were compared
to the ones observed in non-affected control samples; three
resections composed of two cerebral cortex samples from an
unaffected region and one hippocampus sample from a non-
epileptic patient gave Pearson's correlation R = 0.948 (N =
ANOVA test results Figure 1
ANOVA test results. Numbers indicate number of probe sets with 
expression significantly influenced by brain region, source of sample 
material, and their interaction. The interaction term is significant when the 
expression changes due to death differ significantly in the two brain 
regions examined (see Material and methods). Numbers in brackets 
indicate the percentage of significant probe sets compared to the total 
number included in the analysis. Overlapping regions include probe sets 
with more than one significant term.
Region
   5353
 (12.6%)
Source
    4508
 (10.6%)
Source•region
              383
            (0.9%)
  981
(2.3%)
  128
(0.3%)
  108
(0.25%)
   106
(0.25%)http://genomebiology.com/2005/6/13/R112 Genome Biology 2005,     Volume 6, Issue 13, Article R112       Franz et al. R112.3
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2,983, p < 10-15) or using the one hippocampus sample only
gave Pearson's correlation R = 0.905 (N = 4,088, p < 10-15).
Thus, the overwhelming majority of expression differences
between autopsy and resection identified in samples affected
by epileptic condition are also present in the non-affected
samples.
We next asked whether the genes represented by the 4,508
probe sets that showed significant differences in expression
between autopsy and resection samples in both brain regions
cluster in functional categories as defined by the Gene Ontol-
ogy (GO) consortium [12]. Differently expressed genes clus-
tered significantly in all three GO taxonomies, 'biological
process', 'molecular function' and 'cellular component' (p <
0.0001). Among 15 GO 'biological process' categories with
significant over-representation of differently expressed
genes, four are involved in cellular protein metabolism and
six in nucleobase, nucleoside, nucleotide and nucleic acid
metabolism. Most of the remaining genes are found in the
categories 'organelle organization and biogenesis' and 'intra-
cellular protein transport' (Table 2). The expression of genes
involved in the ubiquitin cycle and protein ubiquitination is
significantly increased after death, while the expression of
genes involved in protein biosynthesis, rRNA processing,
organelle organization and biogenesis and induction of apop-
tosis are significantly decreased (two-sided binomial test, p <
0.05).
Among 20 GO categories with significant under-representa-
tion of genes differently expressed between autopsies and
resections, seven are involved in cell communication, three in
response to stimulus, two in sensory perception, and four in
development. In addition, 'cellular physiological process' and
'organismal physiological process' are among the GO catego-
ries that are significantly conserved in their expression
between autopsy and resection samples (Table 2).
In contrast, no chromosome showed either an excess or lack
of expression differences (two-sided binomial test, p  < 0.341,
corrected for multiple testing).
Table 1
Sample information
Sample* Age
(years)
Sex 28S/18S
ratio†
GAPDH 5'/3' 
ratio‡
Expressed
probe sets (%)§
Diagnosis Epilepsy Types of seizures
HA1 70 M 1.2 0.445 50.6 - - -
HA3 45 M 1.6 0.637 49.7 - - -
HA4 45 M 1.2 0.507 49.4 - - -
HA5 54 F 1.6 0.712 51.7 - - -
HR1 45 M 1.1 0.520 50.5 Anaplastisches Oligo WHO III Yes Simple partial
HR2 39 F 1.3 0.700 50.2 Glioblastoma Yes Simple and complex partial, GM
HR3 61 M 1.6 0.774 53.8 Glioblastoma Yes Simple and complex partial
HR4 51 F 1.6 0.697 49.5 Ammon's horn sclerosis Yes Simple and complex partial, GM
HR5 13 M 1.4 0.778 47.1 Ganglioglioma Yes Complex partial
HR6 83 F 1.3 0.817 50.0 Atpisches Meningeom Grad II No -
CA1 45 M 1.4 0.870 51.0 - - -
CA2 45 M 1.4 0.841 51.4 - - -
CA3 48 M 1.5 0.865 53.2 - - -
CA5 70 M 1.4 0.669 47.2 - - -
CA6 82 F 1.7 0.690 47.7 - - -
CA7 67 M NA 0.810 49.5 - - -
CR1 35 F 1.2 0.741 45.9 Focal cortical dysplasia Yes Complex partial, GM
CR2 31 F 1.3 0.741 39.5 Focal cortical dysplasia Yes Simple partial
CR3 9 F NA 0.607 45.6 Focal cortical dysplasia Yes Complex partial
CR4 37 M NA 0.674 43.7 Focal cortical dysplasia Yes Complex partial
CR5 35 F NA 0.737 48.8 Focal cortical dysplasia Yes Complex partial, GM
CR6 31 F NA 0.674 43.1 Focal cortical dysplasia Yes Simple partial
*Sample names: position one = brain region (H, hippocampus; C, cortex); position two = sample source (A, autopsy; R, resection); position three = 
individual. †Ribosomal RNA bands ratio was measured using Agilent 2100 Bionalyzer system. ‡GAPDH ratio was measured using probes to 5' and 3' 
of the transcript on Affymetrix® array. §Expressed probesets were defined based on detection p < 0.05. F, female; GM, grand mal; M, male; NA, not 
applicable.R112.4 Genome Biology 2005,     Volume 6, Issue 13, Article R112       Franz et al. http://genomebiology.com/2005/6/13/R112
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Expression differences between brain regions
To test whether in vivo expression differences between the
brain regions are conserved in postmortem samples, we first
considered the ANOVA results (Figure 1). Among 42,427
probe sets with hybridization signals detectable in at least one
individual, 6,568 (15.5%) showed significant expression dif-
ferences between the two brain regions analyzed (nominal
significance p < 0.01, FDR = 3.6%, permutation test). Out of
these probe sets, 6,431 (97.9%) overlapped with the ones
identified by SAM (FDR = 5%). In 234 of these 6,431 probe
sets, differences between brain regions depended signifi-
cantly on the source of sample material (p  < 0.01). Thus,
although autopsy and resection samples differ substantially
with regard to their gene expression profiles, the patterns of
expression differences between the brain regions remain
largely preserved.
Table 2
Functional analysis of gene expression differences between autopsy and resection samples
GO ID Term Expressed genes Significant differences* Change p value Conservation p value
GO:0006412 Protein biosynthesis 462 101 (37/64) 0.001 0.999
GO:0006512 Ubiquitin cycle 473 119 (86/33) 0.000 1.000
GO:0016567 Protein ubiquitination 256 60 (41/19) 0.002 0.999
GO:0006511 Ubiquitin-dependent protein catabolism 104 36 (23/13) 0.000 1.000
GO:0006396 RNA processing 341 118 (64/54) 0.011 0.995
GO:0006397 mRNA processing 217 74 (44/30) 0.002 0.999
GO:0008380 RNA splicing 183 67 (39/28) 0.000 1.000
GO:0006281 DNA repair 168 40 (23/17) 0.009 0.995
GO:0000398 Nuclear mRNA splicing, via spliceosome 155 54 (30/24) 0.000 1.000
GO:0006364 rRNA processing 32 16 (3/13) 0.000 1.000
GO:0006996 Organelle organization and biogenesis 367 83 (30/53) 0.048 0.964
GO:0006886 Intracellular protein transport 263 62 (32/30) 0.002 0.999
GO:0008624 Induction of apoptosis by extracellular signals 28 13 (2/11) 0.000 1.000
GO:0006120 Electron transport, NADH to ubiquinone 24 10 (3/7) 0.003 0.999
GO:0048247 Lymphocyte chemotaxis 3 3 (0/3) 0.004 1.000
GO:0007242 Intracellular signaling cascade 879 105 0.989 0.016
GO:0007186 GPCR protein signaling pathway 448 39 1.000 0.000
GO:0007267 Cell-cell signaling 417 39 0.998 0.003
GO:0007243 Protein kinase cascade 231 24 0.997 0.005
GO:0045860 Positive regulation of protein kinase activity 41 1 0.999 0.006
GO:0007268 Synaptic transmission 203 18 0.999 0.001
GO:0007187 G-protein signaling (cyclic nucleotide second 
messenger)
73 4 0.999 0.004
GO:0050896 Response to stimulus 1,326 179 0.975 0.035
GO:0009605 Response to external stimulus 781 90 0.972 0.037
GO:0009617 Response to bacteria 37 0 1.000 0.001
GO:0007601 Visual perception 126 9 0.999 0.002
GO:0007606 Sensory perception of chemical stimulus 55 2 0.999 0.003
GO:0007275 Development 1,412 174 0.992 0.011
GO:0009887 Organogenesis 770 89 0.997 0.004
GO:0007417 Central nervous system development 92 6 0.999 0.004
GO:0008544 Epidermis development 39 1 0.999 0.008
GO:0050875 Cellular physiological process 3,372 515 1.000 0.000
GO:0050874 Organismal physiological process 1,200 138 0.997 0.004
GO:0006813 Potassium ion transport 139 3 1.000 0.000
GO:0030003 Cation homeostasis 52 1 1.000 0.001
*Numbers in parenthesis correspond to the number of up- and down-regulated genes in the autopsy samples. Bold font indicates Gene Ontology 
(GO) groups with significant excess of up- or down-regulated genes (see Materials and methods).http://genomebiology.com/2005/6/13/R112 Genome Biology 2005,     Volume 6, Issue 13, Article R112       Franz et al. R112.5
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2005, 6:R112
We tested further whether in vivo expression differences
between the brain regions are conserved in the postmortem
samples by separately identifying, independent of the
ANOVA results, probe sets differently expressed between the
brain regions in the autopsy and in the resection samples.
Using Student's t test with nominal significance p < 0.01, we
found 788 and 3,943 probe sets with a significant difference
in expression between the brain regions in the autopsy and in
the resection samples, respectively (FDR = 22.8% and 4.3%
respectively, permutation test). Similarly, using SAM with
FDR = 5% we found 874 and 6,699 probe sets with a signifi-
cant difference in expression between the brain regions in the
autopsy and in the resection samples, respectively. This large
discrepancy in the numbers of differences between the brain
regions when the autopsy and resection samples are consid-
ered separately seems to contradict the ANOVA results. To
address this, we examined whether probe sets that do not
overlap between these two lists tend to show the same pattern
of change between the brain regions or, alternatively, are
completely uncorrelated in their expression behavior. For
this purpose, we considered all probe sets present on either of
the two lists and calculated the strength of correlation of the
expression difference between the brain regions measured in
the autopsy and in the resection samples. We found a strong
and significant correlation between the expression differ-
ences for both t test (Pearson's correlation R = 0.763, N =
4,471, p < 10-15) and SAM results (Pearson's correlation R =
0.726, N = 7,162, p < 10-15) (Figure 2). Similarly, we found
slightly reduced but still highly significant correlations using
expression differences normalized to the average variation
(effect size) (Pearson's correlation R = 0.566, p < 10-15 and R
= 0.584, p < 10-15, respectively). Thus, expression differences
betweenthe two brain regions are largely concordant in the
autopsy and resection samples. Interestingly, the slopes of the
regression lines (β ) fitted through the distributions of the
expression differences between the two brain regions in the
autopsy and the resection samples equal 0.49 for both sets of
genes (Figure 2). An even stronger effect was observed using
the effect size measurements (β  = 0.33 and β  = 0.32 for t test
and SAM results, respectively). Thus, despite an overall
agreement of the measurements of expression differences in
the two sources of sample material, the amplitude of expres-
sion differences measured in the autopsy samples is, on aver-
age, half of that observed in the resection samples. Limiting
the regression to genes with a high expression difference
amplitude in either autopsy or resection samples did not
change this effect. Interestingly, it was even more pro-
nounced for genes with lower expression in the frontal cortex
compared to the hippocampus (β  = 0.27 and β  = 0.34 for t test
and SAM results, respectively). Since the significance test
depends on the effect size, smaller expression differences
explain the reduced number of identified probe sets in the
autopsy samples.
Influence of death on expression variation
All microarray studies involving postmortem human samples
report substantial biological variation among individuals. We
asked whether death-induced expression changes contribute
to this variation by affecting different individuals to different
degrees. To do this, we examined published gene expression
data from 40 brain autopsy samples [13]. First, we asked
whether probe sets that differ in expression between autopsy
and resection samples vary more among individuals in this
dataset than other probe sets. From the 16,376 probe sets
with a detectable hybridization signal in at least one of the 40
individuals, 1,752 overlap with the probe sets showing signif-
icant differences in expression between autopsy and resection
samples. Using logarithm transformed variation measures,
we found no significant difference between the expression
variation among these probe sets and among the remaining
probe sets (Student's t test, p = 0.916). Thus, genes that differ
in expression between autopsy and resection samples do not
vary more among postmortem samples compared to the other
genes.
Next, we asked whether the amplitude of death-induced
expression changes correlates with the duration of postmor-
tem interval. To test this, we computed correlations between
gene expression levels and postmortem delay in the 40 brain
autopsy samples for 1,752 probe sets that differ in expression
between autopsy and resection samples and for 1,000 subsets
of the same size randomly sampled from the other 14,624
probe sets. In 837 out of 1,000 random subsets, the correla-
tion was greater or equal to the one observed for probe sets
with significant difference in expression between autopsy and
resection samples. Thus, genes that differ in expression
between autopsy and resection samples do not correlate more
with duration of postmortem interval than the rest of the
detected genes.
Scatter plot of expression differences between cortex and hippocampus in  resection (x-axis) and autopsy (y-axis) samples Figure 2
Scatter plot of expression differences between cortex and hippocampus in 
resection (x-axis) and autopsy (y-axis) samples. Expression differences 
were calculated as base two logarithm transformed ratios of gene 
expression values. All probe sets showing significant differences in 
expression levels between the two brain regions, either in the autopsy or 
in resection samples, are plotted: (a) according to Student's t test; (b) 
according to SAM. Red dashed lines represent linear regression results 
and black dotted lines represent expected regression lines with the slope 
= 1.
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Discussion
I n  t h i s  s t u d y ,  w e  o b s e r v e  t h a t  d e a t h  c a u s e s  s u b s t a n t i a l
changes in the expression of more than 10% of genes
expressed in human brain. Furthermore, this change is highly
reproducible, with 96% of differences being shared when two
very different brain regions (frontal cortex and hippocampus)
are considered. Since all brain resection samples were
obtained from people with certain brain abnormalities, an
alternative explanation is that the observed changes are
induced by disease of the living brain rather than by death.
However, for several reasons we find this explanation
unlikely. First, we used resection samples from patients suf-
fering from several different neurological disorders (Table 1),
which are not likely to induce the same pattern of gene
expression change. Second, although all but one of the
patients were diagnosed with epilepsy, severity of the disease
did not significantly influence expression differences between
autopsy and resection samples. Third, we observed similar
gene expression differences between autopsy and resection
samples in both frontal cortex and hippocampus. It is unlikely
that these brain regions are affected in the same way by the
diseases in question. Finally, we found consistent gene
expression differences in the four frontal cortex samples
affected by disease at the histological level and the ones with
normal histology. Taken together, these arguments suggest
that the gene expression differences we observed between
autopsy and resection samples are not due to disease-induced
change in the resection samples.
Still, two factors, epilepsy and surgery, are shared among
most or all patients, respectively. We found no genes with a
significant effect of epilepsy on expression either in hippoc-
ampus or in frontal cortex. Similarly, using data from the
resection samples of non-epileptic patients, we found the
same expression differences between autopsy and resection
samples as we found with epileptic patients' samples. In addi-
tion, known expression changes induced by epilepsy are not
over-represented among differences between autopsy and
resection samples. These results indicate that epilepsy is
unlikely to have contributed a great deal to the expression dif-
ferences we see. Due to the small number of samples used in
the analysis, however, we cannot completely exclude such an
effect. Similarly, we cannot exclude influence of surgery and
surgery related treatments, like anesthesia, on gene expres-
sion in all resection samples. This remains a confounding fac-
tor for estimation of the expression differences between
postmortem and living human brain tissue that we cannot
address in this study.
Yet, given the widespread use of postmortem human brain
tissue in research, the most important question is how well
gene expression differences measured in postmortem sam-
ples reflect those occurring in vivo. We found that despite the
large impact that death as such and, potentially, surgery have
on gene expression patterns in autopsy and resection sam-
ples, respectively, differences between brain regions that exist
in the living brain are mostly retained in postmortem sam-
ples. However, it is striking that the magnitude of the expres-
sion differences between the two brain regions decreases by
approximately 50% on average and that the effect size is
reduced by approximately two-thirds in postmortem sam-
ples. This reduction did not depend on the magnitude of dif-
ference. Interestingly, the reduction was even more
pronounced in genes with lower expression in frontal cortex
than in hippocampus (Figure 2). This indicates that gene
expression differences measured in postmortem brain sam-
ples may underestimate differences existing in the living
tissue.
Interestingly, gene expression changes induced by death do
not appear to increase variation among postmortem brain
samples. In agreement with this, we found no significant cor-
relation between the duration of postmortem interval and the
magnitude of expression differences between autopsy and
postmortem samples. This suggests that expression changes
occur quickly in the process of dying and remain stable there-
after. This observation is in agreement with recent findings
that postmortem delay does not substantially influence gene
expression variation among human brain samples [6-8],
whereas prolonged agonal states significantly influence
expression profiles.
The genes that differ in their expression between autopsy and
resection samples are significantly over- and under-repre-
sented in certain functional processes. Genes involved in
rather basic functions, such as RNA processing, protein bio-
synthesis and transport, organelle organization and biogen-
esis, the ubiquitin cycle, and DNA repair (Table 1) are over-
represented among genes differently expressed between
autopsies and resections. We would have expected an overall
down-regulation of these pathways in tissues after death.
Indeed, genes involved in rRNA processing, protein biosyn-
thesis, induction of apoptosis, and organelle organization and
biogenesis show significant down-regulation in the autopsy
samples. Interestingly, we also see up-regulation of genes
involved in the ubiquitin cycle, protein ubiquitination, and
ubiquitin-dependent protein catabolism. This implies that
death leads to the temporary induction of expression for some
functional processes. It is intriguing to think that death does
not lead to immediate shut down of all functional processes
on a cellular level. If these transcripts become translated to
functional proteins, up-regulation of genes involved in ubiq-
uitin-dependent protein catabolism may lead to increased
degradation of proteins in human brain samples after death.
This could have consequences for protein studies in postmor-
tem human brain samples, where protein degradation is com-
monly observed [14-16]. It may thus be important to compare
protein patterns in postmortem andresection samples of
human brains to estimate the extent of death-induced protein
degradation.http://genomebiology.com/2005/6/13/R112 Genome Biology 2005,     Volume 6, Issue 13, Article R112       Franz et al. R112.7
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More than three quarters of the GO categories with signifi-
cant conservation of their expression levels after death fall
into processes involved in intra- and extracellular signaling
and in development (Table 1). This is rather unexpected since
these processes underlie essential brain functions and genes
involved in such functions have been shown to differ in their
expression levels among various brain regions [17,18]. Intui-
tively, one might expect that death would affect these proc-
esses first. The excess or paucity of expression differences in
certain functional processes could be caused by differences in
RNA degradation rates. In this case we would expect genes
with low RNA turnover to fall into functional categories that
maintain their observed expression levels after death and
genes with high RNA turnover to fall into significantly
changed functional categories. However, genes involved in
signal transduction and development are known to have high
RNA turnover rates [19,20] while genes involved in general
metabolic functions, biosynthesis and catabolism have low
R N A  t u r n o v e r  r a t e s  [ 2 0 , 2 1 ] .  T h u s ,  i t  i s  u n l i k e l y  t h a t  t h e
observed clustering of expression differences in distinct func-
tional categories is due to differences in RNA degradation
rates.
Conclusion
Despite the large effect of death on gene expression in human
brain, postmortem samples maintain the vast majority of the
expression differences that exist between brain regions in
vivo. However, the amplitude of expression differences
between brain regions in postmortem samples is reduced by
approximately 50% compared to the living tissue. It should be
noted that the results reported here examined only a limited
number of samples representing only few conditions and that
confounding effects, including surgery and anesthesia, may
influence some of the expression differences we observe. Nev-
ertheless, given that the primary source of brain tissue is post-
mortem collection, it is encouraging that there is such a high
degree of correlation in gene expression patterns between
sources.
Materials and methods
Tissue samples and microarray data collection
Human postmortem samples were obtained from the
National Disease Research Interchange. Informed consent
for use of the tissues for research was obtained in writing
from all donors or the next of kin. None of the subjects had a
history of neurological disease or had indications of brain
abnormalities at the tissue level as determined at autopsy. All
individuals suffered sudden death for reasons other than
their participation in this study and without any relation to
the tissues used. Human resection samples were obtained
from patients with brain tumors and/or chronic pharmaco-
resistant epilepsy who underwent surgical treatment in the
Surgery/Epilepsy Surgery Programs at the University of Bonn
Medical Center. In all patients, surgical removal of the
tumor/lesion tissue was necessary. Informed consent for
additional studies was obtained in writing from all patients.
The diagnosis of the individual patients is presented in Table
1. All procedures were conducted in accordance with the Dec-
laration of Helsinki and approved by the ethics committees of
the respective institutions. Representative tissue sections
were snap frozen at -80°C. Based on neuropathological anal-
yses by means of hematoxilin and eosin stainings, normal tis-
sue adjacent to the tumor or lesions was used for subsequent
experiments. Intense care was taken to avoid tumor infil-
trated tissue. None of the surgically obtained tissue samples
used in this study, with the exception of four frontal cortex
samples with focal cortical dysplasia, showed any histological
abnormalities. Age, sex, and degree of relatedness of all indi-
viduals are listed in Table 1. 
All samples were processed in parallel starting from the fro-
zen tissue by the same person (HF) in random order with
respect to brain region and the source of sample material.
Total RNA was isolated from approximately 50 mg of frozen
tissue using TRIZol® (GIBCO, San Diego, CA, USA) reagent
according to the manufacturer's instructions and purified
with QIAGEN® RNeasy® kit (Valencis, CA, USA) following
the 'RNA cleanup' protocol. All RNA samples were of high and
comparable quality as determined by the ratio of 28S to 18S
ribosomal RNAs estimated using the Agilent® (Palo Alto, CA,
USA) 2100 Bioanalyser®  system and by the signal ratios
between the probes for the 5' and 3' ends of the mRNAs of
GAPDH used as quality controls on Affymetrix® (Santa Clara,
CA< USA) microarrays (Table 1). Labeling of 1.2 µg of total
RNA, hybridization to Affymetrix®  HG U133plus2 arrays,
staining, washing and array scanning were carried out follow-
ing Affymetrix® protocols. All primary expression data are
publicly available at the ArrayExpress database (accession
number E-TABM-20) [22].
Microarray data analyses
Affymetrix®  microarray image data were collected with
Affymetrix® GeneChip® Operating Software version 1.1 using
default parameters. We used the robust multichip average
(rma) procedure [23] for array normalization and calculation
of expression base two logarithm transformed intensity val-
ues. Since logarithm-transformed intensity values are
a p p r o x i m a t e l y  n o r m a l l y  d i s t r i b u t e d ,  w e  u s e d  t h e m  f o r  a l l
analyses. We calculated detection p values using the Biocon-
ductor 'affy' software package [24]. We defined probe sets
having a detectable hybridization signal using Affymetrix
default detection cutoff of 0.065.
We used ANOVA to identify probe sets that showed a statisti-
cally significant change in expression depending on the brain
region or on the source of sample material among human
samples using the following model: Yij = µj + sourcei + regioni
+ (source*region)i + ε ij. In this equation, Yij is the base two
logarithm of the expression level for probe set j in sample i, µ
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for the effect of the source of sample material, regioni is the
term for the effect of the source of the brain region,
(source*region)i is the term for the interaction effect of the
two factors, and ε ij is the error term. For each term we used a
nominal significance level of 0.01. In order to estimate an
average number of probe sets expected by chance at this sig-
nificance cutoff, we applied the same ANOVA approach to
1,000 datasets constructed by random permutation of the
sample labels in the original data.
Alternatively, differently expressed probe sets were deter-
mined using SAM software version 2.01 with 5% FDR cutoff
[25]. In all cases except the analysis of epilepsy effects, we
performed t statistics on the logarithm transformed expres-
sion values. FDR estimates were based on 500 permutations
of the samples within the set. We used block permutation
design for the two-factor analysis and time course for the
analysis of epilepsy effects. Effect of epilepsy was scored
based on the diagnosis and seizure type: 0, no diagnosed epi-
lepsy; 1, simple partial seizures; 2, simple and complex partial
seizures; 3, complex partial seizures; 4, simple and complex
partial seizures, grand mal; 5, complex partial seizures. Effect
size was calculated as a difference between means divided by
the pooled standard deviation. The pooled standard deviation
was defined as the square root of the average of the squared
standard deviations.
Functional analysis and distribution on chromosomes
To functionally annotate the probe sets on the Affymetrix®
HG U133plus2 arrays, we integrated information from four
public databases: Affymetrix® NetAffx™ (12/2004 release)
[26], LocusLink (12/2004 release) [27], and Gene Ontology
(12/2004 release) [28]. Affymetrix® probe sets were linked to
the corresponding genes using LocusLink annotation pro-
vided by NetAffx™. When a single gene was represented by
multiple probe sets, the gene was classified as detected if at
least one probe set was detected and classified as differen-
tially expressed if at least one probe set was both detected and
differentially expressed. Genes were assigned to their GO
annotations from each of the three GO taxonomies ('molecu-
lar function', 'biological process', and 'cellular component')
using GenMapper [29,30]. Note that a gene belongs to its
assigned GO group as well as all higher groups in the
taxonomy.
To assess if the overall distribution of genes differentially
expressed between autopsy and resection samples across the
groups in a GO taxonomy differs significantly from the distri-
bution of all detected genes, we compared it with 10,000 ran-
dom sets in which the same number of differentially
expressed genes was randomly drawn from the annotated
detected genes as described elsewhere [18]. GO groups with
significant excess and with significant lack of expression dif-
ferences between autopsy and resection samples were deter-
mined independently using the hypergeometric distribution
[18]. The percentage of false positive GO groups was esti-
mated from the ratio of the number of significant groups in
the observed data to the average number of the significant
groups in 10,000 random sets. In the GO taxonomy 'biologi-
cal process', we expect 20% false positives for the groups with
significant excess and 5.8% false positives for the groups with
significant lack of expression differences between autopsy
and resection samples. Significant over-representation of up-
or down-regulated genes in GO groups with significant excess
of expression differences was determined by binomial test.
Probability of up- and down-regulation within a group was
based on distribution of all differently expressed genes. To
assign chromosomal location to genes we used annotation
provided by NetAffx™. Genes differently expressed between
autopsy and resection samples were defined the same way as
for the functional analysis.
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